CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2019	Jul. 01, 2018
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 8,945	$ 7,449
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[3]	3,073	3,129
Asset write-offs and impairments	[3]	178	41
TCJA impact	[3],[5]	(285)	(68)
Deferred taxes from continuing operations	[3]	(160)	(500)
Share-based compensation expense	[3]	384	379
Benefit plan contributions in excess of income	[3]	(313)	(826)
Other adjustments, net	[3]	(462)	(523)
Other changes in assets and liabilities, net of acquisitions and divestitures	[3]	(7,051)	(3,250)
Net cash provided by operating activities	[3]	4,309	5,830
Investing Activities
Purchases of property, plant and equipment	[3]	(939)	(810)
Purchases of short-term investments	[3]	(4,063)	(3,122)
Proceeds from redemptions/sales of short-term investments	[3]	6,001	10,497
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[3]	4,717	1,231
Purchases of long-term investments	[3]	(123)	(1,070)
Proceeds from redemptions/sales of long-term investments	[3]	142	1,361
Acquisitions of intangible assets	[3]	(267)	(32)
Other investing activities, net	[3]	179	138
Net cash provided by investing activities	[3]	5,648	8,193
Financing Activities
Proceeds from short-term borrowings	[3]	3,956	1,746
Principal payments on short-term borrowings	[3]	(2,375)	(2,921)
Net proceeds from short-term borrowings with original maturities of three months or less	[3]	2,719	2,092
Proceeds from issuance of long-term debt	[3]	4,942	0
Principal payments on long-term debt	[3]	(5,355)	(3,104)
Purchases of common stock	[3]	(8,865)	(6,063)
Cash dividends paid	[3]	(4,047)	(4,021)
Proceeds from exercise of stock options	[3]	248	474
Other financing activities, net	[3]	(541)	(831)
Net cash used in financing activities	[3]	(9,318)	(12,628)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[3]	(28)	(15)
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[3]	612	1,381
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[3]	1,225	1,431
Cash and cash equivalents and restricted cash and cash equivalents, end	[3]	1,837	2,811
Non-cash transactions:
Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets	[3],[6]	0	92
Cash paid (received) during the period for:
Income taxes	[3]	2,136	1,197
Interest paid	[3]	809	724
Interest rate hedges	[3]	$ (72)	$ (71)

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] Amounts may not add due to rounding.

[4] Amounts may not add due to rounding.

[5] As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision for taxes on income for (i) the six months ended June 30, 2019 was favorably impacted by approximately $285 million, primarily as a result of additional guidance issued by the U.S. Department of Treasury and (ii) the six months ended July 1, 2018 was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.

[6] For additional information, see Notes to Consolidated Financial Statements––Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Divestitures in our 2018 Financial Report.